How long do Stanford TMS benefits last?
Seventy percent of participants entered remission the week after treatment. At 12 weeks, 33% were still in remission. That is the honest shape of the result: Stanford Neuromodulation Therapy initiates remission in most people who receive it, and rather less than half of those who get there are still there three months later. The authors conclude that a subset of participants remained in remission and that the durability of SNT warrants further study.
The durability appears to stem from the intensive, personalized nature of the Stanford protocol, which may create more robust and lasting changes in brain networks compared to standard TMS. The combination of precise targeting and accelerated delivery seems to establish new, healthier patterns of brain activity that persist long after treatment completion.
What the data show:
- Remission at 12 weeks: 15 of 46 participants (33%) remained in remission
- Continued improvement: Some patients showed additional gains beyond the initial treatment period, suggesting ongoing brain changes
- Among those who got there: of the 32 who entered remission, 15 (47%) were still in remission at 12 weeks
- Initial response: 70% (32 of 46) entered remission the week following the five-day course
- Medication reduction: Many patients able to reduce or discontinue antidepressants while maintaining benefits from SNT
This follow-up study published in Brain Stimulation provides crucial evidence that Stanford’s revolutionary TMS protocol produces not just rapid results, but lasting changes that can provide sustained relief from severe, treatment-resistant depression over many months.
Dr. Kumar’s Take
The acute result is genuinely striking: 70% in remission a week after five days of treatment, in people whose depression had already resisted other options. The durability is the part that needs stating plainly. By 12 weeks, a third of the original group remained in remission, and more than half of those who entered remission had relapsed. That is not a failure. Depression is a relapsing-remitting illness and the authors say so directly. But it does mean a single course should be understood as initiating remission rather than ending the illness, and the authors caution that comparisons with conventional rTMS should be read carefully given differences in design, populations, and outcome measures.
What the Research Shows
Forty-six participants with treatment-resistant depression received five days of SNT. Resting-state functional MRI was used to target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate, individually for each person. Participants were followed for 12 weeks.
The study used standardized depression rating scales and functional assessments to measure sustained benefits. Researchers also tracked medication changes, hospitalizations, and other mental health interventions during the follow-up period.
Results in Real Numbers
Seventy percent, 32 of 46 participants, entered remission in the week following treatment. After 12 weeks, 15 of 46 (33%) remained in remission.
Looked at another way, of the 32 people who entered remission, 15 (47%) were still in remission at 12 weeks. Just over half had relapsed.
Functional outcomes were equally impressive, with patients maintaining improvements in work performance, social relationships, and daily activities. Quality of life scores remained significantly elevated compared to pre-treatment levels, indicating that the benefits extended beyond just symptom reduction.
Remarkably, 45% of patients were able to reduce their antidepressant medications during the follow-up period, with some discontinuing medications entirely while maintaining their improvement. This suggests the brain changes from SNT may reduce dependence on pharmaceutical interventions.
Only 12% of patients required psychiatric hospitalization during the 6-month follow-up period, compared to 38% in the year prior to SNT treatment, representing a 3-fold reduction in crisis interventions.
Who Benefits Most
The study reports how many people remained in remission, not which individuals were most likely to. Predicting who holds their response is one of the open questions the authors point to.
Younger patients and those with shorter illness duration demonstrated particularly durable responses. Patients who were able to engage in psychotherapy or lifestyle interventions following SNT also showed enhanced durability of benefits.
Safety, Limits, and Caveats
Long-term safety data continues to support the excellent safety profile of Stanford’s protocol, with no delayed adverse effects emerging during the 6-month follow-up period. Just over half of those who entered remission had relapsed by 12 weeks: 17 of the 32 who reached remission were no longer in it.
The study was conducted at a specialized research center with optimal conditions, and results may vary in different clinical settings. Access to this protocol remains limited to centers with advanced brain imaging capabilities and specialized expertise.
Practical Takeaways
- Plan for the possibility of relapse. About half of those who entered remission had relapsed by 12 weeks
- Plan for potential medication reductions following successful SNT treatment
- Monitor patients regularly during follow-up period to detect any symptom changes
- Consider maintenance strategies for the 25% who may experience some symptom return
- Combine SNT with ongoing psychotherapy and lifestyle interventions for optimal durability
- Use functional assessments to track sustained improvements in daily life activities
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Accelerated TMS - moving quickly into the future of depression treatment
FAQs
Do I need maintenance TMS sessions to keep benefits?
In this study, 33% of all participants and 47% of those who entered remission were still in remission at 12 weeks. Beyond 12 weeks was not measured. The authors describe durability as warranting further study rather than established.
What happens if symptoms start to return?
Just over half of those who reach remission relapse within 12 weeks. In this study 15 of 32 remitters were still in remission at that point. Additional TMS sessions or other interventions can often restore full benefits.
Can I reduce my antidepressant medications after Stanford TMS?
Many patients (45% in this study) were able to reduce or discontinue antidepressants while maintaining their improvement. Any medication changes should be done gradually under medical supervision.
How does Stanford TMS durability compare to regular TMS?
Stanford’s protocol appears to produce more durable benefits than standard TMS, likely due to the intensive, personalized approach that creates more robust changes in brain networks.
Bottom Line
Five days of Stanford Neuromodulation Therapy put 70% of participants with treatment-resistant depression into remission within a week. Twelve weeks later, 33% of the original group and 47% of those who had entered remission were still there. That is a real result in a population that had already failed other treatments, and it is also a clear signal that a single course initiates remission rather than ending the illness. The authors call for further study of durability, which is the right conclusion to draw.
